IT-hu14.18-IL2

· University of Wisconsin, Madison

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for IT-hu14.18-IL2, covering 2025-04-18 to 2026-06-03. Get the full timeline:

Most recent: Clinical Trial Results: IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma [Phase 1, Phase 2]